PT Kalbe Farma

What PT Kalbe Farma does

PT Kalbe Farma Tbk (IDX: KLBF), founded in 1966 in Jakarta, is Indonesia's largest publicly listed pharmaceutical company and one of the biggest in Southeast Asia, operating through four integrated divisions: Prescription Pharmaceuticals (unbranded generics, branded generics, and licensed drugs distributed to hospitals, pharmacies, and drug stores), Consumer Health (OTC drugs and multivitamins including legacy brands Promag, Mixagrip, Cerebrofort, Fatigon, Xon-Ce, Sakatonik, Entrostop, Kalpanax, Woods, Procold and the newer ZEGAVIT line), Nutritionals (including Hydro Coco coconut water), and Distribution & Logistics (72-branch archipelago network supported by proprietary B2B platforms EMOS for order management and MOSTRANS for transportation). The group runs approximately 16,000 employees across 50 subsidiaries and 22 production facilities with local and international standards.

Name

PT Kalbe Farma

Legal name

PT Kalbe Farma Tbk

Website

https://kalbe.co.id

Company type

Public

Founded year

1966

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

PT Kalbe Farma is Indonesia's largest publicly listed pharmaceutical company, operating across prescription drugs, consumer health, nutritionals, and distribution/logistics. It serves hospitals, pharmacies, and consumers nationwide via 22 production facilities and a 72-branch distribution network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

akta.pro secondary industry

Natural, Organic & Health Foods Wholesale Distribution (CRAOAAAK)

Keywords

• Pharmaceutical manufacturing
• Consumer health products
• Nutritional supplements
• Pharmaceutical distribution services
• Medical device manufacturing

Headquarters

HQ city

Jakarta

HQ country

Indonesia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: Branded generics, unbranded generic drugs, and licensed drugs distributed to hospitals, pharmacies and drug stores. Net sales grew 8.5% YoY in Q1 2026. Company supports National Health Insurance (JKN) program with unbranded generics while strengthening position through innovation in biologics, oncology ecosystems, cell therapy, and vaccines.
2. Consumer Health: Over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks. Net sales grew 3.2% YoY in Q1 2026. Includes leading brands like Promag, Mixagrip, Woods, Fatigon, Xon-Ce, and Cerebrofort. Brand rejuvenation initiatives ongoing.
3. Nutritionals: Nutritional products including lifestyle-oriented and liquid ready-to-drink products for all life stages. Net sales grew 1.6% YoY in Q1 2026. Includes Hydro Coco brand. Focus on premium products and branding initiatives.
4. Distribution and Logistics: Distribution and logistics services with 72 branches across Indonesia. Net sales increased 21.1% YoY in Q1 2026, driven by growth of external principal products. Includes EMOS and MOSTRANS digital platforms.
5. Medical Devices: Medical device manufacturing including CT scanners produced at Forsta facility in Bogor, developed with GE HealthCare partnership. Strategic focus for healthcare resilience.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

PT Kalbe Farma manufactures and distributes prescription pharmaceuticals (unbranded generics, branded generics, and licensed drugs), consumer health products (OTC drugs, multivitamins, supplements such as Promag, Mixagrip, Cerebrofort), nutritional products (including Hydro Coco), vaccines, and medical devices (CT scanners). The company operates an integrated pharmaceutical distribution and logistics network across Indonesia through 72 branches, supported by digital B2B platforms EMOS (order management) and MOSTRANS (transportation).

Product overview

PT Kalbe Farma is a diversified pharmaceutical company with four main divisions: Prescription Pharmaceuticals (generic drugs, branded generics, licensed drugs), Consumer Health (OTC drugs, multivitamins including ZEGAVIT, Promag, Mixagrip, Cerebrofort, Fatigon, Sakatonik, Xon-Ce, Entrostop, Kalpanax, Woods, Procold), Nutritionals (including Hydro Coco brand), and Distribution & Logistics. The company also operates digital B2B services (EMOS for order management, MOSTRANS for transportation). Through subsidiaries like Kalventis Sinergi Farma (vaccines, diabetes and cardiovascular medications), Kalgen DNA (diagnostics including TB KIT), PT Forsta Kalmedic Global (medical device manufacturing with GE HealthCare), and its partnership with LIFE AI (StrokeGENME genetics platform), Kalbe offers a broad healthcare ecosystem spanning pharmaceuticals, consumer health, nutritionals, medical devices, and digital health services across Indonesia with over 50 subsidiaries and 22 production facilities.

Differentiator

Problem solved

Functional benefit

Brands

• ZEGAVIT: Vitamin and supplement brand including ZEGAVIT Gummy Multivitamin variants (ZEGAVIT GLOWME and ZEGAVIT Immu'NFit)
• Promag
• Entrostop
• Kalpanax
• Sakatonik
• Cerebrofort
• Fatigon
• Xon-Ce
• Mixagrip
• Woods
• Procold
• StrokeGENME
• EMOS
• MOSTRANS
• Hydro Coco
• Kalventis

Products and services

• Prescription Pharmaceuticals (Ethicals)

Quantifiable outcome

• Net sales growth of 10.1% YoY to IDR 9.7 trillion in Q1 2026
• +2 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Five partnerships are on record, tiered minor, core and flagship.

• Mandaya Royal Hospital PuriminorStrategic or Co-development Partner · 29 May 2026Health education event collaboration on adult vaccination and EV71 HFMD vaccine for family protection. The event was part of Kalventis's commitment to improving people's awareness on the importance of vaccination as a preventive step to protect all family members.
• LIFE AIcoreStrategic or Co-development Partner · 11 December 2025Partnership to launch StrokeGENME, a genetics-based platform for personalized stroke prevention in Indonesia. The platform aims to reduce stroke rates by providing tailored prevention plans and clinician-guided programs across the country.
• GE HealthCareflagshipStrategic or Co-development Partner · 2 June 2025Partnership to establish Indonesia's first CT scanner production facility at PT Forsta Kalmedic Global in Bogor. The initiative aims to reduce Indonesia's reliance on imported medical imaging equipment, cut delivery times, and improve access to diagnostic technology across the archipelago of over 280 million people. Supports Indonesian government's priority to develop domestic production of ten key medical devices. GE HealthCare also signed a multi-year contract to supply over 300 CT scanners to public hospitals under the SIHREN programme.
• Orange Drugs NigeriacoreStrategic or Co-development PartnerPharmaceutical joint venture in Nigeria as part of Kalbe's international expansion. Nigeria-Indonesia trade relations have grown from approximately £2.08 billion in 2021 to over £3.76 billion by 2023, with Indonesia being Nigeria's second-largest trading partner in Africa.
• ReispirasiminorStrategic or Co-development PartnerEnvironmental collaboration for releasing baby turtles at Samas Beach, Bantul, Yogyakarta, as part of Kalbe's sustainability efforts under the theme 'Sehatkan Alam, Sehatkan Bangsa' (Make the Nature and the Nation Healthier).

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Global pharmaceutical leader with prescription, oncology, and vaccines. Competes with Kalbe in branded prescription drugs and is a benchmark for the oncology/biologics direction Kalbe is pursuing with Serplulimab.
• AstraZeneca: Global biopharma with leading oncology, biologics, and respiratory portfolios. Direct competitor to Kalbe in the oncology/immunology space Kalbe is entering with Serplulimab, and an established player in Indonesian hospital channels.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company and a major emerging-markets pharma player. Comparable in scale, generics-and-specialty mix, and emerging-market distribution depth — a useful template for evaluating Kalbe's regional ambitions.
• Sanofi: Global pharmaceutical MNC with significant prescription, vaccines (including flu), and consumer health portfolios. Competes with Kalbe in biologics, vaccines, and OTC, and historically had a major Indonesia subsidiary (PT Aventis Pharma) now part of the Kalbe ecosystem.
• GSK (Haleon for consumer health): Global pharma and consumer health major. Directly comparable in OTC, multivitamins, and consumer health (the Haleon portfolio), competing in the same Indonesian categories as Promag, Mixagrip, and Cerebrofort.

Direct peers

• Kimia Farma: Indonesia's largest state-owned pharmaceutical company, listed on IDX. Operates prescription pharma, OTC consumer health, distribution, and retail pharmacy networks — the closest direct comparable to Kalbe's diversified model in the same Indonesian market.
• Sanbe Farma: Indonesian pharmaceutical manufacturer focused on prescription drugs and consumer health with established distribution. Comparable as a domestic Indonesian pharma peer with similar therapeutic-class and OTC mix.
• Tempo Scan Pacific: Indonesian pharmaceutical and consumer healthcare group with prescription drugs, OTC brands, and cosmetics. Operates in the same product categories and distribution channels as Kalbe's consumer health and pharma divisions.
• Dexa Medica: Major Indonesian pharmaceutical manufacturer with branded generics, OTC consumer health, and distribution across the archipelago. Comparable in scale, therapeutic focus, and Indonesia-centric distribution model.
• Combiphar: Indonesian pharmaceutical company with branded generics, OTC consumer health, and wellness products. Directly comparable in portfolio mix and Indonesian market focus, though smaller in scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@KalbeFarmaOfficial
• Facebookfacebook.com/KalbeFamily
• LinkedInlinkedin.com/company/pt-kalbe-farma
• Instagraminstagram.com/ptkalbefarmatbk

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries21 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PT Kalbe Farma